Marie O’Farrell
About
Marie O’Farrell is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Marie O’Farrell has authored 25 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cancer Research, 13 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marie O’Farrell's work include Cancer, Lipids, and Metabolism (14 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Lung Cancer Treatments and Mutations (5 papers). Marie O’Farrell is often cited by papers focused on Cancer, Lipids, and Metabolism (14 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Lung Cancer Treatments and Mutations (5 papers). Marie O’Farrell collaborates with scholars based in United States, United Kingdom and France. Marie O’Farrell's co-authors include George Kemble, William McCulloch, Douglas Buckley, Katharine Grimmer, Gregory Duke, Allan S. Wagman, Timothy S. Heuer, Gerald S. Falchook, Andrew Brenner and Emma Dean and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.
In The Last Decade
Marie O’Farrell
25 papers receiving 889 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marie O’Farrell United States | 9 | 486 | 426 | 253 | 126 | 97 | 25 | 901 | ||
| Angélique Gougèlet France | 15 | 602 1.2× | 348 0.8× | 102 0.4× | 184 1.5× | 37 0.4× | 23 | 976 | ||
| Quentin Bayard France | 9 | 302 0.6× | 245 0.6× | 162 0.6× | 105 0.8× | 39 0.4× | 13 | 630 | ||
| Chiara Busletta Italy | 9 | 356 0.7× | 283 0.7× | 299 1.2× | 226 1.8× | 34 0.4× | 15 | 940 | ||
| Zeribe C. Nwosu United States | 15 | 466 1.0× | 295 0.7× | 133 0.5× | 205 1.6× | 19 0.2× | 22 | 884 | ||
| Tomohiko Sakabe Japan | 17 | 475 1.0× | 197 0.5× | 162 0.6× | 248 2.0× | 53 0.5× | 43 | 991 | ||
| Nicolas Dif France | 7 | 319 0.7× | 290 0.7× | 94 0.4× | 188 1.5× | 38 0.4× | 8 | 771 | ||
| Emma Du United States | 12 | 238 0.5× | 104 0.2× | 134 0.5× | 152 1.2× | 67 0.7× | 16 | 586 | ||
| Da Wang China | 16 | 535 1.1× | 341 0.8× | 72 0.3× | 204 1.6× | 17 0.2× | 47 | 914 | ||
| Betty L. Cabrera United States | 16 | 484 1.0× | 260 0.6× | 89 0.4× | 637 5.1× | 50 0.5× | 24 | 1.2k | ||
| Jian Kong China | 19 | 433 0.9× | 345 0.8× | 174 0.7× | 175 1.4× | 38 0.4× | 37 | 1.0k |
Countries citing papers authored by Marie O’Farrell
Since
Specialization
Citations
This map shows the geographic impact of Marie O’Farrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie O’Farrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie O’Farrell more than expected).
Fields of papers citing papers by Marie O’Farrell
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marie O’Farrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie O’Farrell. The network helps show where Marie O’Farrell may publish in the future.
Co-authorship network of co-authors of Marie O’Farrell
This figure shows the co-authorship network connecting the top 25 collaborators of Marie O’Farrell. A scholar is included among the top collaborators of Marie O’Farrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie O’Farrell. Marie O’Farrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Loomba, Rohit, Pierre Bédossa, Katharine Grimmer, et al.. (2024). Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet. Gastroenterology & hepatology. 9(12). 1090–1100.
2.
O’Farrell, Marie, G M Duke, R. Webster Crowley, et al.. (2022). FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Scientific Reports. 12(1). 15661–15661.
3.
Falchook, Gerald S., Jeffrey R. Infante, Hendrik‐Tobias Arkenau, et al.. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 34. 100797–100797.
4.
Loomba, Rohit, Rizwana Mohseni, Kathryn Jean Lucas, et al.. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 161(5). 1475–1486.
5.
Loomba, Rohit, Mary E. Rinella, Stephen A. Harrison, et al.. (2020). Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1). Journal of Hepatology. 73. S53–S54.
6.
Aggarwal, Rahul, Wassim Abida, Michael T. Schweizer, et al.. (2019). Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 79(13_Supplement). CT095–CT095.
7.
Buckley, Douglas, Gregory Duke, Timothy S. Heuer, et al.. (2017). Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target. Pharmacology & Therapeutics. 177. 23–31.
8.
Dean, Emma, Gerald S. Falchook, Manish R. Patel, et al.. (2016). Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.. Journal of Clinical Oncology. 34(15_suppl). 2512–2512.
9.
O’Farrell, Marie, et al.. (2016). Abstract A75: Translational studies of a first-in-class FASN Inhibitor, TVB-2640, linking preclinical studies to clinical laboratory observations in solid tumor patients. Molecular Cancer Research. 14(1_Supplement). A75–A75.
10.
O’Farrell, Marie, R. Webster Crowley, Timothy S. Heuer, et al.. (2015). Abstract 2675: Biomarker and PK/PD analyses of first in class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients. Cancer Research. 75(15_Supplement). 2675–2675.
11.
O’Farrell, Marie, R. Webster Crowley, Timothy S. Heuer, et al.. (2015). Abstract B13: Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients. Molecular Cancer Therapeutics. 14(12_Supplement_2). B13–B13.
12.
Voskoboynik, Mark, Jon Infante, Andrew Brenner, et al.. (2015). 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. European Journal of Cancer. 51. S724–S724.
13.
Brenner, Andrew, Jeffrey R. Infante, Manish R. Patel, et al.. (2015). Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation. Molecular Cancer Therapeutics. 14(12_Supplement_2). A54–A54.
14.
Rewcastle, Gordon W., Jack U. Flanagan, Swarna A. Gamage, et al.. (2014). Abstract 1644: Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR. Cancer Research. 74(19_Supplement). 1644–1644.
15.
Chow, Hoi Yee, Adrian M. Jubb, Zahara M. Jaffer, et al.. (2012). p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model. Cancer Research. 72(22). 5966–5975.
16.
O’Farrell, Marie, Richard Ventura, Albert Tai, & David J. Matthews. (2012). Abstract 3737: The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts. Cancer Research. 72(8_Supplement). 3737–3737.
17.
O’Farrell, Marie, Richard Ventura, Albert Tai, et al.. (2012). Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.. Blood. 120(21). 2907–2907.
18.
Matthews, David J., et al.. (2012). Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 3.
19.
Matthews, David J., et al.. (2011). Abstract 4485: Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR. Cancer Research. 71(8_Supplement). 4485–4485.
20.
Matthews, David J., et al.. (2011). Abstract B160: PWT33597 promotes apoptosis in tumor cells through balanced dual inhibition of PI3K alpha and mTOR.. Molecular Cancer Therapeutics. 10(11_Supplement). B160–B160.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Angélique Gougèlet Breakdown of academic impact, for papers by Quentin Bayard Breakdown of academic impact, for papers by Chiara Busletta Breakdown of academic impact, for papers by Zeribe C. Nwosu Breakdown of academic impact, for papers by Tomohiko Sakabe Breakdown of academic impact, for papers by Nicolas Dif Breakdown of academic impact, for papers by Emma Du Breakdown of academic impact, for papers by Da Wang Breakdown of academic impact, for papers by Betty L. Cabrera Breakdown of academic impact, for papers by Jian Kong